|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Messing EM, Madeb R, Young T, Gilchrist
KW, Bram L, Greenberg EB, Wegenke JD, Stephenson L, Gee J and Feng
C: Long-term outcome of hematuria home screening for bladder cancer
in men. Cancer. 107:2173–2179. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Messing EM, Tangen CM, Lerner SP,
Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans
CP, Hafez KS, et al: Effect of intravesical instillation of
gemcitabine vs saline immediately following resection of suspected
low-grade non-muscle-invasive bladder cancer on tumor recurrence:
SWOG S0337 randomized clinical trial. JAMA. 319:1880–1888. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen X, Wang B, Tian HZ and Gao JZ:
Submucosal injection of anti-tumor drug on the prevention of
Post-TUR-Bt recurrence. Zhonghua Wai Ke Za Zhi. 42:580–582. 2004.In
Chinese. PubMed/NCBI
|
|
5
|
Caffo O, Thompson C, De Santis M, Kragelj
B, Hamstra DA, Azria D, Fellin G, Pappagallo GL, Galligioni E and
Choudhury A: Concurrent gemcitabine and radiotherapy for the
treatment of muscle-invasive bladder cancer: A pooled individual
data analysis of eight phase I-II trials. Radiother Oncol.
121:193–198. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sternberg CN, Bellmunt J, Sonpavde G,
Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ,
Milowsky MI, Theodorescu D, et al: ICUD-EAU international
consultation on bladder cancer 2012: Chemotherapy for urothelial
carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 63:58–66.
2013. View Article : Google Scholar
|
|
7
|
Van QN and Veenstra TD: How close is the
bench to the bedside? Metabolic profiling in cancer research.
Genome Med. 1:52009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bansal N, Gupta A, Mitash N, Shakya PS,
Mandhani A, Mahdi AA, Sankhwar SN and Mandal SK: Low- and
high-grade bladder cancer determination via human serum-based
metabolo-mics approach. J Proteome Res. 12:5839–5850. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jin X, Yun SJ, Jeong P, Kim IY, Kim WJ and
Park S: Diagnosis of bladder cancer and prediction of survival by
urinary metabo-lomics. Oncotarget. 5:1635–1645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Issaq HJ, Nativ O, Waybright T, Luke B,
Veenstra TD, Issaq EJ, Kravstov A and Mullerad M: Detection of
bladder cancer in human urine by metabolomic profiling using high
performance liquid chromatography/mass spectrometry. J Urol.
179:2422–2426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pasikanti KK, Esuvaranathan K, Hong Y, Ho
PC, Mahendran R, Raman Nee Mani L, Chiong E and Chan EC: Urinary
metabotyping of bladder cancer using two-dimensional gas
chromatography time-of-flight mass spectrometry. J Proteome Res.
12:3865–3873. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu X, Cheng X, Liu X, He L, Zhang W, Wang
Y, Sun W and Ji Z: Investigation of the urinary metabolic
variations and the application in bladder cancer biomarker
discovery. Int J Cancer. 143:408–418. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alberice JV, Amaral AF, Armitage EG,
Lorente JA, Algaba F, Carrilho E, Márquez M, García A, Malats N and
Barbas C: Searching for urine biomarkers of bladder cancer
recurrence using a liquid chromatography-mass spectrometry and
capillary electrophoresis-mass spectrometry metabolomics approach.
J Chromatogr A. 1318:163–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou Y, Song R, Ma C, Zhou L, Liu X, Yin
P, Zhang Z, Sun Y, Xu C, Lu X and Xu G: Discovery and validation of
potential urinary biomarkers for bladder cancer diagnosis using a
pseudotargeted GC-MS metabolomics method. Oncotarget.
8:20719–20728. 2017.PubMed/NCBI
|
|
15
|
Shao CH, Chen CL, Lin JY, Chen CJ, Fu SH,
Chen YT, Chang YS, Yu JS, Tsui KH, Juo CG and Wu KP: Metabolite
marker discovery for the detection of bladder cancer by comparative
metabolomics. Oncotarget. 8:38802–38810. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
von Rundstedt FC, Rajapakshe K, Ma J,
Arnold JM, Gohlke J, Putluri V, Krishnapuram R, Piyarathna DB,
Lotan Y, Gödde D, et al: Integrative pathway analysis of metabolic
signature in bladder cancer: A linkage to the cancer genome atlas
project and prediction of survival. J Urol. 195:1911–1919. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Putluri N, Shojaie A, Vasu VT, Vareed SK,
Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C,
et al: Metabolomic profiling reveals potential markers and
biopro-cesses altered in bladder cancer progression. Cancer Res.
71:7376–7386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng Y, Yang X, Deng X, Zhang X, Li P,
Tao J, Qin C, Wei J and Lu Q: Metabolomics in bladder cancer: A
systematic review. Int J Clin Exp Med. 8:11052–11063.
2015.PubMed/NCBI
|
|
19
|
Eidelman E, Tripathi H, Fu DX and Siddiqui
MM: Linking cellular metabolism and metabolomics to
risk-stratification of prostate cancer clinical aggressiveness and
potential therapeutic pathways. Transl Androl Urol. 7(Suppl 4):
S490–S497. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lima AR, Bastos Mde L, Carvalho M and
Guedes de Pinho P: Biomarker discovery in human prostate cancer: An
update in metabolomics studies. Transl Oncol. 9:357–370. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Epstein JI, Amin MB, Reuter VR and Mostofi
FK: The world health organization/international society of
urological pathology consensus classification of urothelial
(transitional cell) neoplasms of the urinary bladder. Bladder
consensus conference committee Am J Surg Pathol. 22:1435–1448.
1998.
|
|
22
|
Sreekumar A, Poisson LM, Rajendiran TM,
Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al:
Metabolomic profiles delineate potential role for sarcosine in
prostate cancer progression. Nature. 457:910–914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu W, Dong T, Wang L, Guan Q, Song L, Chen
D, Zhou Z, Chen M, Xia Y and Wang X: Obesity aggravates toxic
effect of BPA on spermatogenesis. Environ Int. 105:56–65. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Christen S, Lorendeau D, Schmieder R,
Broekaert D, Metzger K, Veys K, Elia I, Buescher JM, Orth MF,
Davidson SM, et al: Breast cancer-derived lung metastases show
increased pyruvate carboxylase-dependent anaplerosis. Cell Rep.
17:837–848. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Davidson SM, Papagiannakopoulos T,
Olenchock BA, Heyman JE, Keibler MA, Luengo A, Bauer MR, Jha AK,
O'Brien JP, Pierce KA, et al: Environment impacts the metabolic
dependencies of Ras-driven non-small cell lung cancer. Cell Metab.
23:517–528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Frolkis A, Knox C, Lim E, Jewison T, Law
V, Hau DD, Liu P, Gautam B, Ly S, Guo AC, et al: SMPDB: The small
molecule pathway database. Nucleic Acids Res. 38:Database Issue.
D480–D487. 2010. View Article : Google Scholar :
|
|
27
|
He YT, Li DJ, Liang D, Zheng RS, Zhang SW,
Zeng HM, Chen WQ and He J: Incidence and mortality of bladder
cancer in China, 2014. Zhonghua Zhong Liu Za Zhi. 40:647–652.
2018.In Chinese. PubMed/NCBI
|
|
28
|
Estrela JM, Ortega A and Obrador E:
Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci.
43:143–181. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Balendiran GK, Dabur R and Fraser D: The
role of glutathione in cancer. Cell Biochem Funct. 22:343–352.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Amelio I, Cutruzzolá F, Antonov A,
Agostini M and Melino G: Serine and glycine metabolism in cancer.
Trends Biochem Sci. 39:191–198. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ke HL, Lin J, Ye Y, Wu WJ, Lin HH, Wei H,
Huang M, Chang DW, Dinney CP and Wu X: Genetic variations in
glutathione pathway genes predict cancer recurrence in patients
treated with transurethral resection and bacillus calmetteguerin
instillation for non-muscle invasive bladder cancer. Ann Surg
Oncol. 22:4104–4110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Patricia Moreno-Londoño A, Bello-Alvarez C
and Pedraza- Chaverri J: Isoliquiritigenin pretreatment attenuates
cisplatin induced proximal tubular cells (LLC-PK1) death and
enhances the toxicity induced by this drug in bladder cancer T24
cell line. Food Chem Toxicol. 109:143–154. 2017. View Article : Google Scholar
|
|
33
|
Boonstra K, Bokelaar R, Stadhouders PH,
Tuynman HA, Poen AC, van Nieuwkerk KM, Witteman EM, Hamann D,
Witteman BJ, Beuers U and Ponsioen CY: Increased cancer risk in a
large population-based cohort of patients with primary biliary
cirrhosis: Follow-up for up to 36 years. Hepatol Int. 8:266–274.
2014.PubMed/NCBI
|
|
34
|
Sundararaghavan VL, Sindhwani P and Hinds
TD Jr: Glucuronidation and UGT isozymes in bladder: New targets for
the treatment of uroepithelial carcinomas? Oncotarget. 8:3640–3648.
2017. View Article : Google Scholar :
|
|
35
|
Duester G, Mic FA and Molotkov A:
Cytosolic retinoid dehydro-genases govern ubiquitous metabolism of
retinol to retinaldehyde followed by tissue-specific metabolism to
retinoic acid. Chem Biol Interact. 143-144:201–210. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Napoli JL: Retinoic acid: Its biosynthesis
and metabolism. Prog Nucleic Acid Res Mol Biol. 63:139–188. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mahmoud LA and Robinson WA: Vitamin A
levels in human bladder cancer. Int J Cancer. 30:143–145. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mettlin C and Graham S: Dietary risk
factors in human bladder cancer. Am J Epidemiol. 110:255–263. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ziouzenkova O, Orasanu G, Sharlach M,
Akiyama TE, Berger JP, Viereck J, Hamilton JA, Tang G, Dolnikowski
GG, Vogel S, et al: Retinaldehyde represses adipogenesis and
diet-induced obesity. Nat Med. 13:695–702. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Serel TA, Soyupek S and Çandir Ö:
Association between mast cells and bladder carcinoma. Urol Int.
72:299–302. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang M, Wei X, Shi L, Chen B, Zhao G and
Yang H: Integrative genomic analyses of the histamine H1 receptor
and its role in cancer prediction. Int J Mol Med. 33:1019–1026.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kerns JC and Gutierrez JL: Thiamin Adv
Nutr. 8:395–397. 2017. View Article : Google Scholar
|
|
43
|
Pamukcu AM, Yalciner S, Price JM and Bryan
GT: Effects of the coadministration of thiamine on the incidence of
urinary bladder carcinomas in rats fed bracken fern. Cancer Res.
30:2671–2674. 1970.PubMed/NCBI
|
|
44
|
Brinkman MT, Karagas MR, Zens MS, Schned
A, Reulen RC and Zeegers MP: Minerals and vitamins and the risk of
bladder cancer: Results from the new hampshire study. Cancer Causes
Control. 21:609–619. 2010. View Article : Google Scholar : PubMed/NCBI
|
